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Abstract
Purpose To explore the characteristics, medical treatments, and long-term facial palsy outcome in Ramsay Hunt syndrome.
Methods Patient questionnaire including self-assessment of long-term facial palsy outcome and retrospective chart review. 
Initial facial palsy grade was compared to self-assessed or patient record stated palsy outcome. Occurrence of different 
characteristics (blisters, hearing loss, vertigo, etc.) of the syndrome were assessed.
Results Altogether 120 patients were included of which 81 answered the questionnaire. All but one patient had received virus 
medication (aciclovir, valaciclovir), and half received simultaneous corticosteroids. If the medication was started within 72 
h of Ramsay Hunt diagnosis, facial palsy recovered totally or with only slight sequelae in over 80% of the patients. Only a 
minority of the patients experienced varicella blisters simultaneously with facial palsy, blisters more often preceded or fol-
lowed the palsy. Approximately 20% of the patients had their blisters in hidden places in the ear canal or mouth.
Conclusions The long-term outcome of facial palsy in medically treated Ramsay Hunt syndrome was approaching the out-
come of Bell’s palsy. It is crucial to ask and inform the patient about the blisters and look for them since, more often than 
not, the blisters precede or follow the palsy and can be in areas not easily seen.
Keywords Herpes zoster oticus · Facial paralysis · Varicella–Zoster virus · House–Brackmann · Sunnybrook · Facial 
grading · Facial sequelae
Introduction
Ramsay Hunt syndrome (RHS) consists of peripheral facial 
palsy (FP) of the VII cranial nerve (CN) and herpes blisters 
in the head and neck area. All nerves that communicate with 
the facial nerve can be involved e.g. CNs V, VIII, IX, and 
X and cervical nerves C2, C3, and C4 [1]. Hearing loss, 
tinnitus, and vertigo frequently accompany facial palsy [2]. 
RHS is caused by reactivation of latent varicella-zoster virus 
(VZV) [2, 3]. Even though cranial polyneuropathy including 
many additional CNs (e.g. III, XI, XII) was not included in 
the original definition of RHS, investigators have reported 
such patients as rare cases of RHS [1, 4, 5].
There are no prospective studies on RHS, specifically. 
Peitersen [6] studied idiopathic peripheral FP and gathered 
all cases throughout 25 years in Copenhagen, Denmark. 
In this group of 2570 FP patients, there were 116 cases of 
RHS. The annual incidence was 2.2/100,000; which was 
approximately 4.5% of all FPs. Estimates of incidence based 
on mostly retrospective studies of individual centers have 
ranged 4–12% of all FPs and around 5/100,000/year [7, 8].
The clinical picture of RHS includes three possibilities 
regarding the timing of the relationship between FP and 
blisters. If the blisters occur before or simultaneously with 
the palsy, RHS diagnosis is usually easy. Sometimes the 
blisters are not very noticeable and can be overlooked by the 
inspector, if RHS is not considered in patients experiencing 
FP. Similarly, in cases where FP presents first, and blisters 
later, clinical RHS diagnosis is impossible at the time of 
palsy onset.
Recognizing RHS has become more important with the 
widely accepted practice of treating these patients with anti-
viral agents along with corticosteroids even though consen-
sus is missing [9–11]. Comparing recovery results from 
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the time before and after the use of antiviral treatments and 
knowing that shingles patients benefit from medical ther-
apy [12, 13], recommendations have been published for the 
combined use of antivirals and corticosteroids [11, 14]. No 
prospective medical studies likely will exist that compare 
different medical treatments to no medications at all in RHS, 
but we can study the patients and how they have recovered in 
order to draw some suggestive conclusions about the treat-
ment results.
The aim of this study was to investigate the characteris-
tics and treatment of RHS and to determine the long-term 
outcome of FP in RHS patients using patient charts retro-
spectively and one-time patient questionnaire.
Materials and methods
A computer search of patient records for RHS from 1/1996 
to 1/2013 was performed in Helsinki University Central 
Hospital, Department of Otorhinolaryngology-Head and 
Neck Surgery. Patients with peripheral FP and a history or 
recognition of blisters in the head and neck area within 1 
month prior, concomitantly with palsy onset, or 1 month 
following the palsy onset, were included in the study. Some 
patients had to be removed from the study, since the history 
of the blisters was indefinite, and one patient because of 
a malignancy behind the symptoms. The time, when RHS 
diagnosis was possible to make, was considered RHS onset.
Besides using the patient records for the data collection, 
the patients were sent a questionnaire asking about their 
RHS symptoms and how they had recovered, and were asked 
to grade their FP outcome.
FP grading methods in patient records varied and both 
House–Brackmann (HB) [15] and Sunnybrook (SB) [16] 
grading scales had been used. For study purposes, SB grades 
were converted to HB grades according to Conversion Table 
[17].
We used SPSS (Armonk, NY: IBM Corp.) versions 22–24 
for statistical analyses. We used descriptive statistics to sum-
marize the frequencies, proportions, medians, and ranges. 
Fischer’s Exact Test was used to calculate the significances.
Results
Patients
Inclusion criteria were met by 120 patients: 71 women 
and 49 men. At the time of the study, 8 of the 120 patients 
had died and 4 could not be reached. The remaining 108 
patients were sent a questionnaire about their RHS. Of these, 
81 answered the questionnaire (52 women, 29 men). The 
caregiver of an additional three patients informed that due 
to the patients’ illnesses, they were no longer capable of 
answering the questionnaire.
Of the 120 patients, 59 experienced FP on the right, and 
61 on the left. Of the 81 patients answering the question-
naire, 40 experienced FP on the right, and 41 on the left.
Age at time of RHS onset for the 120 patients varied from 
6.9 to 94.7 years. The median age for women was 56.4 years 
(range 12.2–94.7), for men 48.8 years (range 6.9–84.3). 
Patients answering the questionnaire were aged 6.9–88.2 
years. The median age was 52.3 years (range 2.2–88.2) for 
women, and 49.1 years (range 6.9–84.3) for men. Five of 
these patients were 16 years or younger at RHS onset.
The median follow-up time for the 81 patients answering 
the questionnaire was 6.6 years (range 1–17.1). For those 
failing to answer the questionnaire, the data were solely col-
lected from the patient records: FP of 26 patients had recov-
ered to total or near total in a median of 3.4 months (range 
0.6–12.1) and no additional follow-up times were scheduled. 
For the remaining 13 (of the 120 patients), 4 were lost in 
follow-up after their initial visit and 9 patients had a follow-
up median of 7.2 months (range 1.2–12.1).
Medical treatment
At RHS onset, all but one of the 120 patients were pre-
scribed either intravenous or oral antiviral medication (aci-
clovir or valaciclovir) (Table 1). Of the prescription-receiv-
ing patients, 57 (48%) were also prescribed concomitant 
corticosteroids (prednisolon or methylprednisolon). One 
patient receiving both aciclovir and prednisolone prescrip-
tion admitted not taking either of the medicines and was 
placed in the “no-medication” group for the outcome results 
in this study.
Of the 120 patients, 104 (87%) received their medication 
within 48 h, an additional 3 (2%) patients within 72 h, 12 
(10%) patients over 72 h from the onset of RHS (one not 
consuming the medication), and 1 (1%) received no medica-
tion at all (Table 1).
Blisters
From patient charts, the location of VZV blisters could be 
identified for 119 patients. The most frequent area to be 
affected was the ear. Outer ear, with or without ear canal 
involvement, was the sole place for blisters in 62 patients 
(52%). In addition, in 7 patients (6%) only the ear canal 
or the ear drum were infected, with no outside visible 
blisters. Taken together, the ear by itself counted for 58% 
of the cases. Ear was additionally involved as follows: 
ear and mouth 4 patients (3%); ear, mouth, and additional 
area 3 patients (2%); and ear and additional area (apart 
from mouth) 15 patients (13%). Thus, the ear was one 
of the areas affected in 91 patients (76%). Mouth cavity 
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Table 1  Long-term outcome of Ramsay Hunt syndrome facial palsy combined from patient records and patient’s self-assessment questionnaire 
and compared to initial facial palsy grade
Medication at Ramsay Hunt syndrome onset Number 
of patients 
(total = 120)
Medication onset time from Ramsay Hunt diagnose/
patient number
Initial HB  gradea –›  outcomeb/patient number
 ≤ 24 h  ≤ 48 h  ≤ 72 h  > 72 h
Valaciclovir orally 1 g × 3 × 7 18 15
HB II –› 1/3
HB III –› 1/1
HB VI –› 2/1
HB ? –› 1/3
HB ? –› 2/6
HB ? –› 3/1
1
HB ? –› 1/1
2
HB II –›1/1
HB ? –› 2/1
Valaciclovir orally, dosing unclear 3 3
HB V –›1/1
HB V –› 2/1
HB ? –› 1/1
Valaciclovir orally 1 g × 3 × 7 + corticosteroidc 41 37
HB II –› 1/1
HB III –› 1/2
HB III –› 4/1
HB IV –› 1/4
HB IV –› 2/2
HB IV –›?/1
HB V –›1/1
HB V –› 2/1
HB V –› 3/1
HB VI –› 1/3
HB VI –› 3/3
HB VI –› ?/1
HB ? –› 1/7
HB ? –› 2/7
HB ? –› 3/2
2
HB II –› 1/1
HB V –› 1/1
1
HB V –› 1/1
1
HB V –› 3/1
Aciclovir orally 800 mg × 5 × 7 9 7
HB III –› 2/1
HB III –› ?/1
HB IV –› 2/1
HB V –›1/1
HB ? –› 1/3
2
HB VI –› 2/1
HB ? –› 1/1
Aciclovir orally 800 mg × 5 × 7 + corticosteroidc 3 3
HB II –› 2/1
HB VI –› 3/1
HB ? –› 1/1
Aciclovir orally, dosing under 800 mg × 5 × 7 or unclear 9 7
HB IV –› 1/1
HB ? –› 1/4
HB ? –›2/2
1
HB ? –› 3/1
1
HB ? –›?/1
Aciclovir intra venous under 10 mg/kg/day × 3 or unclear 3 3
HB II –› 1/1
HB IV –› 1/1
HB ?–› 4/1
Aciclovir orally under 800 mg × 5 × 7 or intra venous under 10 
mg/kg/day × 3 + corticosteroidc
3 3
HB II –› 1/1
HB V –› 2/1
HB ? –›1/1
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was solely affected in 14 patients (12%) and in addition 
to prementioned times with ear, in 2 patients (2%) mouth 
was affected with other area facial blisters. Face, neck, 
and shoulders without ear or mouth involvement were 
affected in 12 patients (10%).
VZV blisters preceded FP in 58 patients (48%), were 
concomitant in 19 patients (16%), and followed the palsy 
onset in 43 patients (36%).
From 58 patients’ charts, the time difference between 
the blisters appearing before FP could be assessed: 1–2 
days prior in 15 cases (26%), 3–7 days prior in 25 cases 
(43%), 8–14 days prior in 13 cases (22%), and over 14 
(≤ 30) days prior in 5 cases (9%).
The information about the time difference between 
FP preceeding blisters could be obtained from 43 patient 
charts: 1–2 days prior in 20 cases (46%), 3–7 days prior 
in 17 cases (40%), 8–14 days prior in 3 cases (7%), and 
over 14 (≤ 30) days prior in 3 cases (7%).
Hearing loss
An audiogram had been taken from 103 patients; In 54 
(52%) there was an acute hearing loss linked to the RHS. 
In 8 of these cases, there was a mention that the hearing 
loss was mild (the audiogram itself was not obtainable). No 
comprehensive audiometry testing could be found at the end 
of the follow-up time for all the study patients. Of those 81 
patients answering the questionnaire, 18 (22%) answered 
that they were left with a hearing loss after the illness, 7 
(9%) were not sure, and 56 (69%) answered they had no 
hearing loss because of RHS.
Other symptoms
From the patient charts (n = 120), mentions of accompaning 
symptoms could be gathered from 110 patients: symptoms 
around the affected ear 86 (78%) (ache, fullness e.g.), ache 
Patients are grouped by the medication type and medication start time at syndrome onset
a Initial facial palsy grade was available from 62 patient records, graded by House-Brackmann scale (HB) or Sunnybrook scale, latter converted 
here to HB grades
b Facial palsy outcome: 1—totally recovered; 2—slight sequelae; 3—obvious sequelae; 4—severe sequelae
c Corticosteroid usually Prednisolon 60 mg/day with tapering dosing 10 mg/day after 5 days for 10 days or Medrol 32 mg or 64 mg/day for 7–10 
days
Table 1  (continued)
Medication at Ramsay Hunt syndrome onset Number 
of patients 
(total = 120)
Medication onset time from Ramsay Hunt diagnose/
patient number
Initial HB  gradea –›  outcomeb/patient number
 ≤ 24 h  ≤ 48 h  ≤ 72 h  > 72 h
Aciclovir intra venous minimum 10 mg/kg/day × 3 19 14
HB II –›1/1
HB III –›1/1
HB V –› 1/1
HB V –› 2/1
HB V –› 3/1
HB VI –› 2/1
HB VI –› 3/1
HB ? –› 1/3
HB ? –› 2/2
HB ? –› 4/1
HB ? –›?/1
2
HB ? –› 1/1
HB ? –› 1/1
3
HB II –› 3/1
HB II –›1/1
HB VI –› 4/1
Aciclovir intra venous minimum10 mg/kg/day × 3 + corticoster-
oidc
10 7
HB II –› 2/1
HB IV –› 1/1
HB V –› 1/2
HB V –› 3/1
HB VI –› 4/1
HB ? –› 2/1
1
HB V –› 2/1
2
HB ? –› 3/1
HB ? –›1/1
No medication 2 2
HB ? –› 2/1
HB ? –› 3/1
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in some other area 24 (22%), vertigo/dizziness 34 (31%), 
and additional mentions of nausea, vomiting, tinnitus, and 
hyperacusia.
Of the 81 patients answering the questionnaire, 73 com-
mented on the symptoms from the acute period of RHS 
onset: ache around the affected ear 56 (77%), vertigo/diz-
ziness 37 (51%), hearing loss 33 (45%), and dryness of the 
affected eye 31 (42%). Other frequently mentioned symp-
toms were nausea, tinnitus, dysgeusia, vomiting, and dry-
ness of the mouth. At the questionnaire’s open area for extra 
reporting “other areas of pain” was mentioned frequently. 
For the questions about persistent symptoms after minimum 
of 1 year recovery time 26 (32%) mentioned having persis-
tent vertigo or dizziness because of the RHS, 5 (6%) patients 
were not sure, and 50 (62%) experienced no balance dis-
turbances. Tinnitus was experienced by 24 (30%) patients, 
dry mouth by 21 (26%), facial numbness by 21 (26%), and 
excessive tearing by 23 (28%).
Immunocompromised patients
Altogether 12 (10%) of the 120 patients either had an illness 
or took medication that made them immunocompromised 
and could have predisposed them to RHS.
FP or RHS history
Amongst those 81 patients answering the questionnaire, 7 
(9%) had a relative who had experienced FP. No one had a 
relative with RHS history. There was one patient with previ-
ous FP from which she was totally cured. Two patients had 
suspected a new FP after the RHS, but there were no patient 
charts for review of the incidence and the symptoms had 
disappeared in a day or two. There were no patients with 
recurrent RHS.
FP recovery from patient questionnaire
Table 2 shows the FP outcome of patient self-assessment 
from the questionnaire. There was no statistical difference in 
outcome, whether the patient received “gold standard” shin-
gles virus medication or whether the amount of the medica-
tion was unclear (Tables 2, 3, 4). Similarly, there was no 
statistical difference whether the medication included cor-
ticosteroids or not. The outcome stayed the same as long as 
the medication was started within 72 h of RHS onset with 
64 (84%) of the patients totally cured or left only with slight 
sequelae (Tables 2, 3, 4). In total paralysis (HB VI) the FP 
outcome to total or good recovery with medication within 
72 h was achieved by 3 of the 7 patients (43%) (Tables 3, 4). 
Already in HB grade V, the recovery to that same grade was 
achieved by 5 of 7 and 8 of 10 patients (70–80%) (Tables 3, 
4).
The number of patients receiving their medication later 
than 72 h or taking no medication at all was low, only 6 (7% 
of 81), but regardless of the initial FP grade, none recovered 
totally and only 2 (33% of 6) recovered to having only slight 
sequelae (Table 2).
FP recovery from patient records and questionnaire 
combined
Combining questionnaire results and patient chart results, FP 
outcome could be estimated to 116 (97%) of the 120 patients 
(Tables 1, 5). Of all the patients, 107 (89%) received virus 
medication (± corticosteroids) within 72 h and for 103 of 
them (96%) a long-term FP outcome could be determined; 
87 (84%) were cured totally or were left only with slight 
sequelae (Tables 1, 5). Two patients (2%) took no medica-
tions and for 11 (9%) patients the medication was started 
over 72 h from the RHS onset. FP outcome was known for 
12 of these 13 patients: 7 (58%) were cured totally or were 
left only with slight sequelae; and 5 (42%) were left with 
obvious or severe sequelae. The patient number in each ini-
tial HB grade was as follows: HB II, 3; HB V, 1; HB VI, 2; 
and HB?, 7. A Fisher’s two-sided Exact Test failed to reach 
significance (P = 0.060) when comparing the results of these 
two groups: those receiving any medication within 72 h and 
those receiving medication over 72 h from RHS onset or 
none at all. Tables 5, 6, 7, and 8 show that there was no 
significant difference on FP long-term outcome between the 
different types of medications. Initial total paralysis seamed 
to lead to worse outcome results in all medication groups 
(Tables 1, 5, 6, 7, 8).
Discussion
FP outcome
In our study, good recovery (total recovery or recovery with 
only slight sequelae; comparable to HB grades I and II [17]) 
was obtained by over 80% of the patients receiving anti-
viral therapy within 72 h from RHS onset. These results 
are in concordance with results from other studies where 
medical therapy (antivirals ± corticosteroids) has been used. 
Even though in our study almost all patients received antivi-
ral therapy, only half received simultaneous corticosteroid 
treatment. A good recovery rate has been reported by Uri 
et al. [18] for 26/31 (83%) patients (HB I & II); Murakami 
et al. [14] for 65/80 (81%) (HB I & II); Shim et al. [1] for 
223/328 (68%) (HB I & II); Kiniski [19] for 85/91 (93%); 
Zainine et al. [20] for 10/15 (67%) (HB I & II); and Coul-
son et al. [21] for 60/101 (59%) (HB I & II). Before the use 
of virus or combination medication, worse recovery results 
were reported. In Peitersen’s study [6], “fair recovery” with 
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Table 2  Long-term outcome of Ramsay Hunt syndrome facial palsy by patient’s self-assessment questionnaire compared to the initial facial 
palsy grade
Medication at Ramsay Hunt syndrome onset Number 
of patients 
(total = 81)
Medication onset time from Ramsay Hunt diagnose/patient 
number
Initial HB  gradea –› patient self-graded facial palsy 
 outcomeb/patient number
 ≤ 24 h  ≤ 48 h  ≤ 72 h  > 72 h
Valaciclovir orally 1 g × 3 × 7 10 9
HB II –› 1/1
HB III –› 1/1
HB VI –› 2/1
HB ? –› 1/2
HB ? –› 2/4
1
HB ? –› 1/1
Valaciclovir orally, dosing unclear 3 3
HB V –›1/1
HB V –› 2/1
HB ? –› 1/1
Valaciclovir orally 1 g × 3 × 7 + corticosteroidc 32 28
HB II –› 1/1
HB III –› 1/2
HB III –› 4/1
HB IV –› 1/2
HB IV –› 2/2
HB V –› 2/1
HB V –› 3/1
HB VI –› 1/1
HB VI –› 3/3
HB ? –› 1/7
HB ? –› 2/5
HB ? –› 3/2
2
HB II –› 1/1
HB V –› 1/1
1
HB V –› 1/1
1
HB V –› 3/1
Aciclovir orally 800 mg × 5 × 7 6 5
HB III –› 2/1
HB IV –› 2/1
HB ? –› 1/3
1
HB VI –› 2/1
Aciclovir orally 800 mg × 5 × 7 + corticosteroidc 2 2
HB II –› 2/1
HB ? –› 1/1
Aciclovir orally, dosing under 800 mg × 5 × 7 or unclear 5 4
HB IV –› 1/1
HB ? –› 1/2
HB ? –›2/1
1
HB ? –› 3/1
Aciclovir intra venous under 10 mg/kg/day × 3 or unclear 2 2
HB II –› 1/1
HB ?–› 4/1
Aciclovir orally under 800 mg × 5 × 7 or intra venous under 10 
mg/kg/day × 3 + corticosteroidc
3 3
HB V –› 2/1
HB II –› 1/1
HB ? –›1/1
Aciclovir intra venous minimum 10 mg/kg/day × 3 12 10
HB II –›1/1
HB III –›1/1
HB V –› 2/1
HB V –› 3/1
HB VI –› 2/1
HB ? –› 1/2
HB ? –› 2/2
HB ? –› 4/1
1
HB ? –› 1/1
1
HB II –› 3/1
Aciclovir intra venous minimum10mg/kg/d × 3 + corticosteroidc 4 3
HB II –› 2/1
HB V –› 1/1
HB VI –› 3/1
1
HB ? –› 3/1
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either full recovery or only mild sequelae was reported in 
46% of cases, and in a study by DeVriese et al. [7] only 30% 
recovered to HB I & II. Our results, even with antivirals as 
the only medication, were amongst the best recovery results 
published. The previous use of acyclovir could also worsen 
the outcome results compared to the later and present use 
of valasiclovir with easier dosing regimen. It remains to be 
seen whether the outcome results continue to improve with 
the wider usage of newer antivirals (e.g. famciclovir) as sug-
gested in the study by Kim et al. [22].
When comparing the recovery results to the initial HB 
grade, the low patient numbers in each HB grade made 
statistically significant conclusions impossible, but there 
seemed to be a clear drop in the possibility of a favorable 
outcome if the paralysis was total at the onset. An outcome 
with only slight sequelae or better was only a little over 
a Initial facial palsy grade was available from 40 patient records, graded by House-Brackmann scale (HB) or Sunnybrook scale, latter converted 
here to HB grades
b Facial palsy outcome by patient’s own assessment: 1—totally recovered; 2—slight sequelae; 3—obvious sequelae; 4—severe sequelae
c Corticosteroid usually Prednisolon 60 mg/day with tapering dosing 10 mg/day after 5 days for 10 days or Medrol 32 mg or 64 mg/day for 7–10 
days
Patients are grouped by the medication type and medication start time at syndrome onset
Table 2  (continued)
Medication at Ramsay Hunt syndrome onset Number 
of patients 
(total = 81)
Medication onset time from Ramsay Hunt diagnose/patient 
number
Initial HB  gradea –› patient self-graded facial palsy 
 outcomeb/patient number
 ≤ 24 h  ≤ 48 h  ≤ 72 h  > 72 h
No medication 2 2
HB ? –› 2/1
HB ? –› 3/1
Table 3  Outcome of facial palsy by patient’s self-assessment questionnaire in comparison to initial facial palsy grade with patients (total num-
ber = 75) receiving any amount of virus medication (± corticosteroid) within 72 h from Ramsay Hunt syndrome onset
House–Brackman (HB) facial palsy grade at 
Ramsay Hunt syndrome onset
Totally cured (1): 
patient number/%
Slight sequelae (2): patient 





HB II 6/75% 2/25%; 100%
HB III 4/67% 1/16%; 83% 1/16%
HB IV 3/50% 3/50%; 100%
HB V 4/40% 4/40%; 80% 2/20%
HB VI 1/14% 2/29%; 43% 4/57%
HB ? 21/55% 12/32%; 87% 3/8% 2/5%
Total patient number/% per 75 patients 39/52% 24/32%; (1 + 2) 84% 9/12% 3/4%
Table 4  Outcome of facial palsy by patient’s self-assessment questionnaire in comparison to initial facial palsy grade with patients (total number 
62) receiving maximal virus medication (± corticosteroid) within 72 h from Ramsay Hunt syndrome onset
House–Brackman (HB) facial palsy grade at 
Ramsay Hunt syndrome onset
Totally cured (1): 
patient number/%
Slight sequelae (2): patient 





HB II 4/67% 2/33%; 100%
HB III 4/67% 1/16%; 83% 1/16%
HB IV 2/40% 3/60%; 100%
HB V 3/43% 2/28%; 71% 2/28%
HB VI 1/14% 2/29%; 43% 4/57%
HB ? 17/55% 11/36%; 91% 2/6% 1/3%
Total patient number/% per 62 patients 31/50% 21/34%; (1 + 2) 84% 8/13% 2/3%
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40%, whereas already in HB V with any used virus medi-
cation it was 70–80%. Still, the outcome seemed better 
than for those receiving no medication or starting it later 
than 72 h although the patient number in both these groups 
was so small that the results were easily affected by any 
single patient’s outcome.
The mantra we all have probably repeated, that patients 
with RHS recover worse than those with Bell’s palsy, is still 
Table 5  Outcome of facial palsy (known for 103 patients) by patient 
records and patient’s self-assessment questionnaire in comparison to 
the initial facial palsy grade with patients (total number 107) receiv-
ing any amount of virus medication (± corticosteroid) within 72 h 
from Ramsay Hunt syndrome onset
House–Brackman (HB) facial palsy 
grade at Ramsay Hunt syndrome 
onset
Totally cured (1); 
patient number/%










HB II 8/80% 2/20%; 100%
HB III 4/67% 1/16%; 83% 1/16% 1
HB IV 7/70% 3/30%; 100% 1
HB V 8/50% 5/31%; 81% 3/19%
HB VI 2/20% 2/20%; 40% 5/50% 1/10% 1
HB ? 27/53% 18/35%; 88% 4/8% 2/4% 1
Total patient number/% per 103 
patients
56/54% 31/30%; (1 + 2) 84% 12/12% 4/4% 4 (4% of 107 patients)
Table 6  Outcome of facial palsy (known for 86 patients) by patient 
records and patient’s self-assessment questionnaire in comparison to 
the initial facial palsy grade with patients (total number 90) receiving 
maximal amount of virus medication (± corticosteroid) within 72 h 
from Ramsay Hunt syndrome onset
House–Brackman (HB) facial palsy 
grade at Ramsay Hunt syndrome 
onset
Totally cured (1): 
patient number/%








Outcome not known: 
patient number
HB II 6/75% 2/25%; 100%
HB III 4/67% 1/ 16%; 83% 1/16% 1
HB IV 5/62% 3/38%; 100% 1
HB V 7/54% 3/23%; 77% 3/23%
HB VI 2/20% 2/20%; 40% 5/50% 1/10% 1
HB ? 21/51% 16/39%; 90% 3/7% 1/3% 1
Total patient number/% per 86 
patients
45/52% 27/31%; (1 + 2) 83% 11/13% 3/4% 4 (4% of 90 patients)
Table 7  Outcome of facial palsy (known for 52 patients) by patient 
records and patient’s self-assessment questionnaire in comparison to 
initial facial palsy grade with patients (total number 54) receiving any 
amount of virus medication with corticosteroids within 72 h from 
Ramsay Hunt syndrome onset
House–Brackman (HB) facial palsy 
grade at Ramsay Hunt syndrome 
onset
Totally cured (1): 
patient number/%








Outcome not known; 
patient number
HB II 3/60% 2/40%; 100%
HB III 2/67% 0/0%; 67% 1/33%
HB IV 5/71% 2/29%; 100% 1
HB V 5/50% 3/30%; 80% 2/20%
HB VI 3/38% 0/0%; 38% 4/50% 1/12% 1
HB ? 9/47% 8/42%; 89% 2/11%
Total patient number/% per 52 
patients
27/52% 15/29%; (1 + 2) 81% 8/15% 2/4% 2 (4% of 54 patients)
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likely to be true, but the gap might not be as wide as we have 
thought. If we assess Bell’s palsy patients meticulously, the 
end result, even with corticosteroid treatment, is that about 
30% of the patients are left with some degree of sequelae, 
although mostly slight [23]; not very different from the 
results achieved in this study.
Hearing loss
About half of our study patients experienced hearing loss at 
some point of the illness, with only 20% reporting constant 
hearing loss after the illness. Since this result was based on 
patients’ own reports, other reasons for hearing loss (e.g. 
prespyacusis) could also influence the outcome. In the study 
by Coulson et al. [21], 42% of the patients reported hearing 
loss and 50% had hearing deterioration on the affected site 
on audiometric measurement (any asymmetry to the unaf-
fected side). Shin et al. [24] reported hearing loss in 74% of 
the patients studied (≥ 10 dB difference to the unaffected 
side). Neither of these retrospective studies commented on 
the end result of the hearing loss. In Peitersen’s prospective 
FP study [6], 73% of the RHS patients had hearing loss. He 
states as a rule that the hearing loss is non-reversible. This 
was not true in our study, even amongst those patients that 
underwent end-outcome audiometry tests—many recovered. 
The same view was presented by Wayman et al. [25], with 
only 5% of the patients with residual hearing loss after RHS.
Blisters
In our study, herpes blisters were most often found in the 
ear, followed by the mouth cavity, but also to a minor extent 
without ear or mouth involvement in other parts of the head 
and neck. In Peitersen’s study [6], the ear was affected in 
66% of cases, face in 15%, and mouth cavity in 9%. In a 
study by Coulson et al. [21], inclusion criteria for the study 
consisted of blisters only in the ear or mouth, with the ear 
affected in 85% of the cases, mouth in 7%, and both in 8% 
of the cases.
With our patients, the herpes blisters preceded the FP in 
48% of the cases, were simultaneous in 16%, and followed 
the FP in 36% of the cases. In Peitersen’s study [6], blis-
ters occurred first in 60% of the cases, were simultaneous 
in 25%, and followed FP in 15% of the cases. Aizawa et al. 
[3] found that blisters preceded the palsy 31%, occurred 
at the same time as the palsy 52%, and followed the palsy 
15%. Hato et al. [26] found a difference between children 
and adults in the way that blisters followed FP in 32% of 
adults, but even in 50% of children 16 years or younger. In 
our study, over one third of the RHS diagnoses could not 
be made at FP onset because the blisters were yet to come. 
It is a serious reminder to advise the patients to be alert of 
blisters appearing after FP. It is very probable that some of 
these patients are lost for diagnosis and treatment in cases 
of blisters following FP.
In our study design, we set the time boundaries for the 
herpes blisters to be 1 month before or after the FP and some 
patients showed the blisters 14–30 days before or after FP. 
In the study by Aizawa et al. [3], the blisters were seen from 
27 days before to 13 days after the FP. They studied the viral 
load and immune responses of the patients and concluded 
that FP in RHS can occur at different times, from early phase 
to the regression phase of VZV reactivation, and that there 
are variable patterns of development of facial nerve dys-
function induced by VZV reactivation and the progression 
of neuritis.
Strengths and limitations
The strength of this study was the rare long-term outcome 
assessment of FP by self-assessment of a rather large group 
of patients. The exploration of many different characteristics 
of RHS was also valuable, revealing, among other things, 
Table 8  Outcome of facial palsy (known for 51 patients) by patient 
records and patient’s self-assessment questionnaire in comparison to 
initial facial palsy grade with patients (total number 53) receiving any 
amount of virus medication without corticosteroids within 72 h from 
Ramsay Hunt syndrome onset
House–Brackman (HB) facial palsy 
grade at Ramsay Hunt syndrome 
onset
Totally cured (1): 
patient number/%








Outcome not known; 
patient number
HB II 5/100%
HB III 2/67% 1/33%; 100% 1
HB IV 2/76% 1/33%; 100%
HB V 3/50% 2/33%; 83% 1/17%
HB VI 2/67%; 67% 1/33%
HB ? 17/55% 10/32%; 87% 2/6% 2/6% 1
Total cure patient number/% per 51 
patients
29/57% 16/31%; 1 + 2/88% 4/8% 2/4% 2 (4% of 53 patients)
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the knowledge that with over one third of the patients, the 
blisters appeared after FP onset and in 20% of the patients 
the blisters were hidden in the ear canal or in the mouth, and 
could not be seen if not looked for.
A limitation of the study was that the protocol failed to 
permit standardized gradings of FP from the patient records 
at the baseline visit or at the end of the follow-up period. 
Facial function evaluations varied from brief mentions of 
“almost total paralysis”, “slight weakness”, “almost cured”, 
or “well cured” to the use of both HB and SB grading scales. 
The study data was collected already several years ago and 
goes back over 20 years. We hope that our routines on evalu-
ating FP patients are more coordinated today than what they 
were in the 1990s, and that the SB grading scale is frequently 
used also by residents who usually first meet these patients 
in the outpatient clinics. In addition, the time the patient 
was first seen and evaluated after FP onset and the length of 
the follow-up varied between patients. The time gap from 
RHS onset to answering the questionnaire was also long in 
some cases, which likely affected how the patient was able 
to remember and answer about the symptoms at the disease 
onset. Finally, the number of patients in subgroups was also 
too small to draw statistically liable conclusions.
Conclusions
Medication seems to significantly advance the outcome 
of RHS, thus it is important to recognize the disease. In 
our study, only 16% of patients displayed blisters occuring 
simultaneously with FP, so it is crucial to ask the patients 
about preceding blisters and inform them about the pos-
sibility of blisters occurring after FP. In addition, 18% of 
our patients experienced their blisters at the ear canal or in 
the mouth, hidden from view, therefore it is imperative to 
meticulously check the patient throughout.
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